Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25081053 | 0.85 | AADAT (0.41) | FFAR4NAMPTMETAP1ACHE | |
| SCHEMBL14457829 | 0.80 | FFAR1 (0.42) | FFAR4DGAT1FFAR1ITGB3ITGA2B | |
| SCHEMBL8730184 | 0.80 | MAPT (0.50) | DGAT1FFAR1ITGB3ITGA2BNAMPT | |
| SCHEMBL7293280 | 0.79 | TBXA2R (0.42) | FFAR4DGAT1FFAR1ITGB3ITGA2B | |
| SCHEMBL6673906 | 0.79 | ITGB3 (0.41) | DGAT1FFAR1ITGB3ITGA2B | |
| SCHEMBL9245560 | 0.79 | PNMT (0.44) | DGAT1ITGB3ITGA2BNAMPTMETAP1 | |
| SCHEMBL22344890 | 0.79 | SLC6A4 (0.46) | FFAR4DGAT1FFAR1ITGB3ITGA2B | |
| SCHEMBL14439411 | 0.79 | ELANE (0.41) | FFAR4DGAT1FFAR1ITGB3ITGA2B | |
| SCHEMBL10226240 | 0.79 | CYP19A1 (0.54) | FFAR4FFAR1ITGB3ITGA2BACHE | |
| SCHEMBL20584776 | 0.78 | TRPM5 (0.42) | METAP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| EP-0372484-B1 | Condensed benzene derivative | ZERIA PHARM CO LTD (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5028604-A | Cognition Activators | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0372484-A2 | Condensed benzene derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | FFAR4 54/4885DGAT1 754/4885FFAR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.